

IMPACT REPORT

**Hope, Healing and
Discovery: Your Impact on Cancer
Research**

Presented to:

Desert Mountain CARE

August 2025

Your Generosity Heals, Extends and Improves Lives



Together We Make a Difference

Desert Mountain CARE's unwavering partnership with HonorHealth has touched the lives of countless patients with cancer and their loving families.

Through your extraordinary generosity, totaling more than \$4 million over the years, you've fueled world-class cancer research and offered our patients the most precious gift of all - time. Time for promising discoveries. Time to live with greater comfort and dignity. Time with the people they love most.

Because of you, HonorHealth is able to provide compassionate, expert care in state-of-the-art facilities while driving the kind of leading-edge research that brings hope, healing and life-saving innovation.

From all of us at HonorHealth and the families you continue to uplift: thank you. Your generosity is changing lives!



"Your visionary generosity allows us to steadfastly deliver on our mission of providing exceptional care and groundbreaking research."

On behalf of our staff and the community we serve, I thank you for your kindness and commitment to the well-being of others."

—TODD LAPORTE
CEO

Where Healing Begins and Innovation Takes Flight

2024-25

The Rare Cancer Initiative partnership between Desert Mountain CARE and HonorHealth Research Institute continues to align our progress with the vision of making a difference in the lives of our patients and their families.

Our focus has evolved into areas of:

- Drug delivery (pEVs, gas marbles, pSiNPs)
- Bedside testing
- Clinical trials for rare cancers
- Biomarker analysis for uveal melanoma and GIST
- Development of the ASTEROIDS/organoid platform

Because of you, our Translational Research Project portfolio includes:

- Advanced drug nano-delivery systems
 - pSiNP and in vitro validation in ASTEROIDS for uveal melanoma and radiation therapy
 - Plant extracellular vesicles (PEVs) for small drugs, metals and RNA therapeutics
 - Controlled engineering by vertical farming
 - Gas marble therapeutics - fabrication, validation and future applications
- Point-of-care monitoring of gene and cell therapies
 - Vertical Flow Immunoassay platform for Cytokines Release Syndrome

UVEAL MELANOMA PROGRAM TRANSFORMATION

With Support from Desert Mountain CARE:

- HRI is now an established Uveal Melanoma Center of Excellence
 - We offer among the largest number of treatment options for patients with uveal melanoma
 - Hepzato - One of the first centers in the US; Currently helping other centers open their programs
 - Four clinical trials specifically for uveal melanoma
- First site open, first site to dose a patient and current lead enroller in Replimune's Registrational Phase 3 study of RP2
- Will be the first and lead US site for Phase 2 study of PI3K Delta specific inhibitor in uveal melanoma
- Developed strong partnerships with uveal melanoma patient advocacy groups
 - Helped kick-off A Cure In Sight fundraiser and awareness 5Ks
 - Hosted 2024 Eye Believe Survivorship Thrivorship Patient Seminar attended by patients internationally online and in-person

Clinical Research

Investigator Initiated Trial of Tumor Treating Fields (TTF) combined with Nivolumab and Ipilimumab

- Accrual complete as of Dec. 2024. Currently running translational studies on biopsies and blood samples
- Clinical response data is pending - One patient received a single cycle of treatment and had to discontinue due to side effects. That patient is still in follow-up 19 months later **without** disease progression. Median OS for untreated uveal melanoma is currently 16-20 months

Because of You...

We Came:

- Courage and skills to take on the most difficult cancers and cancer needs

We Saw:

- Identified unmet needs in uveal melanoma, tenosynovial giant cell tumor and gastrointestinal stromal tumor
- Asking the right questions and creating the right partnerships towards the benefit of our patients
- Merging the prior DM CARE support in cellular therapy (organoids) and imaging to create a better platform for patient-oriented questions

We Conquered:

- Emerging data for gas marbles with potential for use in cancer, stroke, heart attacks, burn patients and wounds/ulcers
- PEVs represent not only a novel technology for treatment delivery of chemotherapy, but we hypothesize that they can be used to deliver genetic programming for elements such as CAR-T therapy
- VFI technology, developed for space use can be employed for enhancing safety of new cellular and immunotherapy
- Patent positioning for all the above with plans to move forward with additional grants and commercialization

Future plans:

- Longevity: How do we help people enhance not only their quality of life but their length of life?
Interception:
 - Prevent relapse in at-risk individuals with cancer
 - Intervene in cases with evidence of molecular relapse
 - Prevent cancer in patients with underlying genetic risk to reduce the need for surgery that changes patient's lives

Desert Mountain CARE -
Thank you for your continued kindness, generosity
and support!